Celldex Therapeutics (CLDX) Non-Current Debt (2010 - 2013)

Celldex Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $4.4 million for Q1 2013.

• In Q1 2013, Non-Current Debt fell 55.25% year-over-year to $4.4 million; the TTM figure through Mar 2013 stood at $4.4 million (down 55.25% YoY), while the FY2012 annual figure was $5.7 million, down 36.21% from the prior year.
• Non-Current Debt was $4.4 million for Q1 2013 at Celldex Therapeutics, down from $5.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $15.0 million in Q1 2011 to a low of $4.4 million in Q1 2013.
• Historically, Non-Current Debt has averaged $9.5 million across 4 years, with a median of $9.4 million in 2011.
• The sharpest annual moves came in 2012 and 2013: Non-Current Debt surged 38.06% in 2012, then sank 55.25% in 2013.
• A 4-year view of Non-Current Debt shows it stood at $8.9 million in 2010, then advanced by 1.34% to $9.0 million in 2011, then tumbled by 36.21% to $5.7 million in 2012, then slipped by 22.97% to $4.4 million in 2013.
• The last three Non-Current Debt figures came in at $4.4 million (Q1 2013), $5.7 million (Q4 2012), and $7.3 million (Q3 2012), per Business Quant data.